Isconova AB
Kungsgatan 109
Uppsala
SE-751 83
Tel: 46-18-161700
Fax: 46-18-161701
Website: http://www.isconova.se/
25 articles about Isconova AB
-
Isconova Interim Report January – June 2013
8/27/2013
-
Isconova Applies for Delisting
8/22/2013
-
Novavax, Inc. Acquires Isconova; Extends Public Tender Offer Period for Remaining Isconova Shareholders
7/31/2013
-
Novavax, Inc. and Isconova to Combine; Novavax' Swedish Prospectus Approved
7/8/2013
-
Novavax, Inc. Offers to Buy All Outstanding Shares of Isconova for $29.6 Million
6/4/2013
-
Isconova to Present at "Influenza Vaccines for the World Conference"
10/11/2012
-
Isconova's Adjuvant Matrix-M in Clinical Trial With Malaria Vaccine
10/8/2012
-
Isconova Carries Out a Fully Guaranteed Rights Issue of Approximately SEK 50 Million
8/27/2012
-
Isconova's Adjuvant Matrix-M Approved by FDA for an IND Clinical Trial
8/15/2012
-
Isconova Concludes Partnership With Virbac S.A.
7/25/2012
-
Isconova to Present Matrix-M™ Adjuvant at Modern Vaccines Adjuvants & Delivery Systems Conference
6/29/2012
-
Isconova - Interim Report January-March 2012
5/29/2012
-
Successful Phase I Study Using Isconova's Matrix MTM Adjuvant
5/14/2012
-
Isconova (publ.) - Year-end Report January-December 2011
2/28/2012
-
Isconova Appoints Sven Andreasson as New CEO
2/23/2012
-
Rabies Vaccines With Isconova's Matrix-M™ Adjuvant Launched in Russia
2/8/2012
-
Isconova - Interim Report January – September, 2011
11/29/2011
-
Positive Avian Flu Trial Data Using Isconova's Matrix M(TM) Published
8/29/2011
-
Isconova and Genocea Biosciences Expand Collaboration
8/22/2011
-
Russell Greig Appointed Acting CEO for Isconova
8/18/2011